TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patient and Provider Interventions for Managing Osteoarthritis in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* radiographic evidence of hip OA and / or radiographic of or meets clinical criteria for knee OA~* current joint symptoms~* BMI \>=25~* physically inactive~Exclusion Criteria:~* Diagnosis of rheumatoid arthritis, fibromyalgia, or other systemic rheumatic disease~* Hospitalized for a stroke, myocardial infarction or coronary artery revascularization in the past 3 months~* Active diagnosis of psychosis or serious personality disorder~* On waiting list for / planning arthroplasty~* Severely impaired hearing or speech (patients must be able to respond to phone calls)~* Unable to speak English~* No access to a telephone~* Participating in another OA intervention or other lifestyle change study~* Dementia or other memory loss condition~* Current, uncontrolled substance abuse disorder~* Motor neuron diseases, Parkinson's Disease, multiple sclerosis~* Quadriplegic or paraplegic~* Serious / terminal illness as indicated by referral to hospice or palliative care~* Other self-reported health problem that would prohibit participation in the study~* Nursing home resident~* Other health conditions or personal issues judged by a study team member or primary care physician to make the patient inappropriate for the study~* Female participants: pregnant or planning to become pregnant~* Metastatic Cancer~* History of gout in knee or hip~* Total joint replacement (knee or hip) surgery, other knee or hip surgery, meniscus tear (verified by MRI), or ACL tear in the past 6 months~* Have not seen their VA-assigned primary health care provider for more than a year

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: NO_INTERVENTION): usual care
- Arm 2 (Type: EXPERIMENTAL): Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* able and willing to provide written informed consent~* diagnosed with chronic plaque psoriasis~* 3% to 15% body surface area involved~* in good general health~Exclusion Criteria:~* other current treatments for psoriasis~* renal or liver dysfunction~* pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): LCD Solution: 2 applications / day
- 2 (Type: ACTIVE_COMPARATOR): Calcipotriol cream: 2 applications / day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients at least 1 year of age and weighing more than 10kg.~* Microscopic diagnosis P. knowlesi (including diagnosis as P. malariae) or P. falciparum infection (any parasitaemia).~* Negative P. falciparum malaria rapid diagnostic test (histidine rich protein 2)~* Fever (temperature ≥37.5°C) or history of fever in the last 48 hours.~* Able to participate in the trial and comply with the clinical trial protocol.~* Written informed consent to participate in trial; thumbprint is required for illiterate patients, and written consent from parents/guardian for children below age of consent.~Exclusion Criteria:~* Clinical or laboratory criteria for severe malaria, including warning signs, requiring parenteral treatment according to modified WHO criteria (see Appendix 4)~* Parasitaemia \> 20,000 /μL~* Inability to tolerate oral treatment~* Concomitant infection with any other malaria species~* Positive for P. falciparum histidine-rich-protein-2 by malaria rapid diagnostic test~* Pregnancy or lactation~* Unable or unwilling to use contraception during study period~* Known hypersensitivity or allergy to artemisinin derivatives~* Serious underlying disease (cardiac, renal or hepatic)~* Received anti-malarials in previous 2 months~* Previous psychiatric illness or epilepsy~* Previous episode of cerebral malaria

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine.~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; \>35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, \>10-15kg = 1 tablet.
- Chloroquine (Type: ACTIVE_COMPARATOR): Chloroquine.~1 tablet contains 155mg chloroquine base. Adult dose (\>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (\>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy for Adolescent Binge Eating and Loss of Control Eating

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: To be included, adolescents must:~1. Be in the age range ≥12 years old and ≤17 years old;~2. Have a BMI that places them above the 85th percentile based on their age and sex;~3. Report 2 episodes of binge/LOC eating (feeling a loss of control while eating) per month for the past 3 months;~4. Be otherwise-healthy youth (i.e., no uncontrolled or serious medical conditions);~5. Read, comprehend, and write English at a sufficient level to complete study-related materials;~6. Be available for participation in the study for 7 months.~Exclusion Criteria: Prospective participants will be excluded if the adolescent:~1. Has a medical or psychiatric condition that would require hospitalization or intensive care (e.g., neurological disorder, psychotic disorders, suicidality);~2. Has a medical or psychiatric condition that would prohibit them from engaging in behavioral treatment or moderate physical activity (e.g., cardiovascular problems);~3. Has uncontrolled medical condition(s) (e.g., uncontrolled diabetes or hypertension);~4. Is pregnant or breastfeeding;~5. Is taking medication(s) or participating in treatment(s) that could influence weight or appetite;~6. Began taking hormonal contraceptives less than 3 months prior;~7. Has a developmental or cognitive disorder (e.g., autism spectrum disorder);~8. Has a concurrent feeding/eating disorder (e.g., bulimia nervosa); or~9. Is participating in another clinical research study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive-Behavioral Therapy (Type: EXPERIMENTAL): Adapted Cognitive-Behavioral Therapy (CBT) for adolescents with binge eating or loss-of-control eating.
- Control Condition (Type: OTHER): Educational materials related to adolescent health and nutrition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Furosemide for Accelerated Recovery of Blood Pressure Postpartum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertensive disorder of pregnancy diagnosed antepartum or intrapartum~* Gestational hypertension~* Pre-eclampsia with or without severe features~* Superimposed pre-eclampsia with or without severe features~* New diagnosis of HDP within 24 hours from delivery~* Postpartum, delivery ≥ 20 weeks estimated gestational age~* Age ≥18 years old~Exclusion Criteria:~* History of allergic reaction to furosemide~* High risk comorbidities for which treatment may be indicated or contraindicated: class C or higher diabetes mellitus, chronic kidney disease or baseline creatinine \>1.2, cardiac disorders including cardiomyopathy, congenital heart disease, angina or coronary heart disease, rheumatic disease (lupus), sickle cell disease~* Baseline labs with K \<3~* Use of furosemide or other diuretics antepartum or intrapartum~* Use of ototoxic agents including aminoglycosides (ie, Gentamicin for \>1 dose), cephalosporins (ie Ancef \>1 dose),~* Patient unstable for protocol per investigator's judgement

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Oral furosemide (Type: EXPERIMENTAL): Oral furosemide 20 mg/day for a total of 5 consecutive doses.
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Placebo once per day for a total of 5 consecutive doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of allergic asthma \>= 1 year duration and a history consistent with Step 2 or 3 clinical features from the Global Initiative for Asthma guidelines.~* Eligible baseline serum immunoglobulin E (IgE) levels value and body-weight combinations~Exclusion Criteria:~* Documented medical history of anaphylaxis~* Lung disease other than mild to moderate allergic asthma such as chronic obstructive pulmonary disease (COPD)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Omalizumab 900 mg
- 2 (Type: EXPERIMENTAL): Omalizumab 1050 mg
- 3 (Type: EXPERIMENTAL): Omalizumab 1200 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients 18 to 80 years of age, self-identified as Hispanic or Latino ethnicity~* Females must be post-menopausal, or not pregnant and using an approved contraceptive regimen~* Meet criteria for stage I or II hypertension~* Currently not treated, or being treated with no more than two anti-hypertensive medications~Exclusion Criteria:~* Secondary hypertension~* Are taking three or more antihypertensive agents~* Have uncontrolled or poorly controlled diabetes mellitus type I or type II~* Evidence of other concurrent disease or conditions that might interfere with the conduct of the study~* Participation in any investigational study within 30 days of Screening (Visit 1).~* Have a history of hypersensitivity to nebivolol or other β-blockers, or any contraindication to β-blocker use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: ACTIVE_COMPARATOR): Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Suspicion of acute appendicitis and planned for diagnostic laparoscopy and eventual laparoscopic appendectomy~* Perforated appendicitis (diagnosed during surgery by the surgeon)~* Negative p-HCG (women)~* Written informed consent after written and verbal information (preoperatively for the intervention group and postoperatively for the control group)~Exclusion Criteria:~* Cannot understand, read or speak Danish~* Previous allergic reaction to fosfomycin, metronidazole, rhGM-CSF, or penicillins e.g. piperacillin or amoxicillin~* Diagnostic laparoscopy revealing normal appendix not requiring an appendectomy or appendicitis without perforation~* Other intra-abdominal pathology requiring surgical intervention at the same operation~* Known renal or hepatic disease or biochemical evidence at the time of admission~* Known hematologic disease in current medical treatment~* American Society of Anesthesiologists (ASA) physical status ≥4 (a patient with severe systemic disease that is a constant threat to life)~* Body weight \>110 kg~* Surgery converted to open appendectomy~* Anticipated compliance problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): None
- Control group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of nonpsychotic MDD (single or recurrent) for at least 4 weeks before study entry~* In good general medical health~* Normal intelligence~Exclusion Criteria:~* Lifetime history of any psychotic disorder, including psychotic depression~* Lifetime history of bipolar I and II disorders~* Alcohol or substance dependence within the 6 months before study entry~* Anorexia nervosa or bulimia within the 6 months before study entry~* Pregnant or breastfeeding females, or sexually active females not using medically acceptable means of birth control (e.g., IUD, birth control pills, barrier devices)~* Chronic medical illness (medically unstable and requires regular medication that may interfere with treatment interventions)~* Concurrent medication(s) with psychotropic effects (e.g., anticonvulsants, steroids, etc.) other than stable ADHD medication~* First degree relatives with bipolar I disorder~* Severe suicidal ideation or previous history of serious suicide attempt within this episode~* Prior failure to respond to an adequate treatment with fluoxetine (defined as at least 40 mg/day for 4 weeks)~* Non-English speaking

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Continued medication alone (Type: ACTIVE_COMPARATOR): Participants will receive antidepressant treatment with fluoxetine for 30 weeks
- Continued medication plus CBT (Type: EXPERIMENTAL): Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patient with a diagnosis of detrusor overactivity associated with a neurological condition;~* Use clean intermittent catheterization~* On stable dose of oral oxybutynin before participation~Exclusion Criteria:~* Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency~* Have any medical condition that precludes their participation in the study or may confound the outcome of the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Oxybutynin Transdermal System (Type: EXPERIMENTAL): Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
- Oral oxybutynin (Type: ACTIVE_COMPARATOR): 5 to 15 mg/day immediate release or extended release tablets, or syrup

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Men or women, at least 18 years of age, with evidence of moderate renal impairment (an eGFR ≥ 30 and \<60 mL/min/1.73 m2) and myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI).~Exclusion Criteria:~* Symptoms, biomarker elevation or electrocardiogram (ECG) changes other than those of the index event that are consistent with a diagnosis of AMI but are likely not due to primary myocardial ischemia~* Ongoing hemodynamic instability~* Planned coronary artery bypass surgery~* Evidence of hepatobiliary disease~* History of acute kidney injury (AKI) after previous exposure to an intravenous contrast agent.~* History of nephrotic range proteinuria.~* Known history of allergy to soy beans or peanuts, immunoglobulin A (IgA) deficiency, antibodies to IgA , or hypersensitivity to CSL112 or any of its components.~* Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CSL_112 (Type: EXPERIMENTAL): CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed advanced or metastatic colorectal cancer~  * Unresectable disease~* At least 1 bidimensionally measurable lesion~  * At least 2 cm in perpendicular diameters~* No evidence of CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 to 75~Performance status:~* 0-1~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin normal~* SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 1.25 times ULN~Cardiovascular:~* No clinically significant cardiac disease~* No congestive heart failure~* No New York Heart Association class III or IV heart disease~* No symptomatic coronary artery disease~* No uncontrolled cardiac arrhythmia~* No myocardial infarction within the past year~Gastrointestinal:~* No evidence of dysphagia~* No malabsorption or intestinal obstruction that would affect absorption or excretion of study drugs~* No chronic diarrhea~Other:~* No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer~* No psychiatric disability that would preclude study compliance~* No other significant medical condition~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for advanced or metastatic disease~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* At least 4 weeks since prior major surgery to the gastrointestinal tract~Other:~* No concurrent therapy for history of seizures or CNS disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
- Arm B (Type: ACTIVE_COMPARATOR): Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete